Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma

Cancer

Volumn 98, Issue 8, 2003, Pages 1603-1610

  Hellerstedt, Beth ^a   Pienta, Kenneth J ^a,b   Redman, Bruce G ^a,b   Esper, Peg ^a   Dunn, Rodney ^b   Fardig, Judith ^a   Olson, Karin ^a   Smith, David C ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Androgen independent prostate carcinoma cyclophosphamide; Diethylstilbestrol; Prednisone

Indexed keywords

ANTIANDROGEN; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; FOLINIC ACID; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TEGAFUR; URACIL; WARFARIN;

ACUTE LEUKEMIA; ADULT; AGED; ANDROGEN BLOOD LEVEL; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; BONE PAIN; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CATHETER ABLATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DOSE TIME EFFECT RELATION; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LYMPHOCYTOPENIA; MALE; NEUROPATHY; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; RAT; SEPSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; URETER OBSTRUCTION;

ADMINISTRATION, ORAL; AGED; ANDROGENS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RATS; TUMOR CELLS, CULTURED;

EID: 0141958312     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11686     Document Type: Article

References (33)

1. Smith DC. Chemotherapy for hormone refractory prostate cancer. Urol Clin North Am. 1999;26:323-331.
2. Robertson CN, Roberson KM, Padilla GM, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst. 1996;88:908-917.
3. VACURG. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet. 1967;124: 1011-1017.
4. Blackard CE, Byar DP, Jordan WP Jr. Orchiectomy for advanced prostatic carcinoma. A reevaluation. Urology. 1973; 1:553-560.
5. Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group Phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol. 1995;28:273-283.
6. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984; 311:1281-1286.
7. Garnick MB. Leuprolide versus diethylstilbestrol for previously untreated Stage D2 prostate cancer. Results of a prospectively randomized trial. Urology. 1986;27(1 Suppl):21-28.
8. Citrin DL, Résnick MI, Guinan P, et al. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial. Prostate. 1991;18:139-146.
9. Waymont B, Lynch TH, Dunn JA, et al. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol. 1992;69:614-620.
10. Beck PH, McAnich JW, Goebel JL, Stutzman RE. Plasma testosterone in patients receiving diethylstilbestrol. Urology. 1978;11:157-160.
11. Kent JR, Bischoff AJ, Arduino LJ, et al. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol. 1973;109:858-860.
12. Bailar JC III, Byar DP. Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer. 1970;26:257-261.
13. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988;7:165-170.
14. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology. 1998;52:257-260.
15. Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int. 2000;85:1069-1073.
16. Kyaduno M, Yamaguchi S, Matsumiya K, Osafune M. Intermittent intravenous high-dose cyclophosphamide therapy in advanced prostatic cancer with distant metastasis. Hinyokika Kiyo. 1989;11:1865-1869.
17. Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol. 1996;14:1617-1625.
18. Stephens RL, Vaughn C, Lane M, et al. Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. Cancer. 1984;53:406-410.
19. Muss HB, Howard V, Richards F II, et al. Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. Cancer. 1981;47:1949-1953.
20. Herr HW. Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer. J Urol. 1982;127:462-465.
21. Wozniak AJ, Blumenstein BA, Crawford ED, Boileau M, Rivkin SE, Fletcher WS. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Cancer. 1993; 71:3975-3978.
22. Saxman S, Ansari R, Drasga R, et al. Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study. Cancer. 1991;70:2488-2492.
23. Murphy GP, Priore RL, Scardino PT. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus Adriamycin, cis-platinum plus 5- fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial. Urology. 1988;32:33-40.
24. Kasimis BS, Miller JB, Kaneshiro CA, Forbes KA, Moran EM, Metter GE. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM) in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. J Clin Oncol. 1985;3: 385-392.
25. Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, Roe DJ. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res. 1987; 47:2723-2726.
26. Abell FL, Wilkes JD, Divers L, Huben R, Velagapudi S, Raghavan D. Oral cyclophosphamide (CTX) for hormone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol. 1995;14:243.
27. Raghavan D, Cox K, Pearson BS, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol. 1993;72:625-628.
28. Maulard-Durdux C, Dufour B, Hennequin C, Chretien Y, Delanian S, Housset M. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer. 1996;77:1144-1148.
29. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
30. Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a Phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol. 2001;19: 62-71.
31. Esper PS, Pienta KJ, Cella D. FACT-P: a new instrument for quality of life evaluation in prostate cancer [abstract]. J. Urol. 1995;153:42a.
32. Oh WK. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer. 2000;88(12 Suppl):3015-3021.
33. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21:2123-2137.